Climb Bio (CLYM) Accumulated Expenses (2020 - 2026)

Climb Bio's Accumulated Expenses history runs 7 years deep, the most recent figure standing at $984000.0 for Q1 2026.

• Quarterly Accumulated Expenses fell 83.88% year-over-year to $984000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $984000.0 (down 83.88% YoY) and the FY2025 annual result came in at $4.5 million, up 9.58% from the prior year.
• Accumulated Expenses was $984000.0 for Q1 2026 at Climb Bio, down from $4.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $6.1 million in Q1 2025 and bottomed at $914000.0 in Q2 2025.
• A 5-year average of $3.4 million and a median of $3.0 million in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses soared 496.46% — and 2026, when it sank 83.88%.
• Climb Bio's Accumulated Expenses stood at $5.0 million in 2022, then tumbled by 51.79% to $2.4 million in 2023, then surged by 67.24% to $4.1 million in 2024, then grew by 9.58% to $4.5 million in 2025, then tumbled by 77.93% to $984000.0 in 2026.
• Business Quant data shows CLYM's Accumulated Expenses at $984000.0 in Q1 2026, $4.5 million in Q4 2025, and $1.5 million in Q3 2025.